Volume 17, Number 10—October 2011
CME ACTIVITY - Research
Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006
Table 4
Antifungal drug | Mucorales, no. (%), n = 105 | Fusarium spp., no. (%), n = 37 | Scedosporium spp., no. (%), n = 27 | Total, no. (%), N = 169 |
---|---|---|---|---|
Received before diagnosis | ||||
Amphotericin B† | 7 (6.7) | 5 (13.5) | 3 (11.1) | 15 (8.9) |
Fluconazole | 35 (33.3) | 17 (45.9) | 5 (18.5) | 57 (33.7) |
Itraconazole | 13 (12.4) | 4 (10.8) | 8 (29.6) | 25 (14.8) |
Voriconazole | 47 (44.8) | 10 (27.0) | 3 (11.1) | 60 (35.5) |
Caspofungin | 18 (17.1) | 3 (8.1) | 3 (11.1) | 24 (14.2) |
Posaconazole | 0 | 1 (2.7) | 0 | 1 (0.6) |
Received after diagnosis | ||||
Amphotericin B† | 82 (78.1) | 19 (51.4) | 9 (33.3) | 110 (65.1) |
Fluconazole | 4 (3.8) | 0 | 0 | 4 (2.4) |
Itraconazole | 10 (9.5) | 2 (5.4) | 8 (29.6) | 20 (11.8) |
Voriconazole | 39 (37.1) | 20 (54.1) | 15 (55.6) | 74 (43.8) |
Caspofungin | 26 (24.8) | 12 (32.4) | 11 (40.7) | 49 (29.0) |
Posaconazole | 24 (22.9) | 3 (8.1) | 3 (11.1) | 30 (17.8)
*TRANSNET, Transplant-Associated Infection Surveillance Network. Numbers do not total 100% because of concomitant receipt of multiple antifungal agents. |
*TRANSNET, Transplant-Associated Infection Surveillance Network. Numbers do not total 100% because of concomitant receipt of multiple antifungal agents.
†Any amphotericin B formulation.
Page created: September 23, 2011
Page updated: September 23, 2011
Page reviewed: September 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.